ABIVAX Société Anonyme (NASDAQ:ABVX) Raised to “Strong-Buy” at Citizens Jmp

ABIVAX Société Anonyme (NASDAQ:ABVX) was upgraded by Citizens Jmp to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

Separately, JMP Securities assumed coverage on shares of ABIVAX Société Anonyme in a research report on Wednesday. They set an “outperform” rating and a $33.00 price objective for the company. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $38.67.

ABIVAX Société Anonyme Price Performance

Shares of ABVX stock opened at $8.33 on Wednesday. The stock’s 50 day simple moving average is $9.85 and its 200 day simple moving average is $11.61. ABIVAX Société Anonyme has a twelve month low of $8.06 and a twelve month high of $17.02.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its position in shares of ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after acquiring an additional 5,900 shares in the last quarter. Walleye Capital LLC raised its position in ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after purchasing an additional 80,807 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after purchasing an additional 119,300 shares during the period. Finally, abrdn plc boosted its holdings in ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.